Ultime notizie per Mynd.ai (AMEX:MYND) Azioni

Mynd.ai

Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more. Geographically, it operates in United States and Rest of the world.

Mynd.ai Inc

MYND LIFE SCIENCS INC by MYND Life Sciences Inc.

MYND Life Sciences Inc

WIIM

NVDA

NVIDIA shares are trading lower following reports indicating China's Huawei Technologies has developed an AI chip to challenge the company.

Mizuho analyst Gabriel Moreen maintains Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Outperform and lowers the price target from $226 to $218.

News

Price Target

Analyst Ratings

TRGP

Mizuho Maintains Outperform on Targa Resources, Lowers Price Target to $218

AAPL

'Apple's iPhone 17 Has Completed Its Engineering Verification Phase, But The Supply Chain Conservatively Forecasts A Double-Digit Year-On-Year Shipment Decline In 2025 Due To The Trump Administration's Aggressive And Fluctuating Tariff Policies. These Tariffs Also Impact iPad, Macbook, And Wearable Device Shipments, With Production Shifting Partially From China To India And Vietnam Amid Ongoing Economic Uncertainties.' - DigiTimes Alert

Wedbush analyst Richard Anderson maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and lowers the price target from $24 to $22.

Wedbush Maintains Outperform on Healthpeak Properties, Lowers Price Target to $22

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">94.80</td>
<td align="right">0.44</td>
<td align="right">0.46</td>
<td>1.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.14</td>
<td align="right">0.12</td>
<td align="right">0.24</td>
<td>141.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.87</td>
<td align="right">0.03</td>
<td align="right">0.03</td>
<td>1.1K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">208.13</td>
<td align="right">-0.34</td>
<td align="right">-0.17</td>
<td>16.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">137.86</td>
<td align="right">-0.19</td>
<td align="right">-0.14</td>
<td>4.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">82.30</td>
<td align="right">-0.09</td>
<td align="right">-0.11</td>
<td>9.0K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

Leading And Lagging Sectors For April 28, 2025

Cemex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) shares are trading higher premarket on Monday. The company reported first-quarter net sales of $3.65 million, missing the consensus of $3.80 billion.
Net sales <a target="_blank" href="https://www.cemex.com/w/cemex-reports-record-first-quarter-net-income-new-ceo-with-strong-commitment-to-bolster-shareholder-return" rel="noreferrer noopener">fell </a>7% year over year (Y/Y), mainly due to lower volumes in Mexico.
Mexico sales declined 25% Y/Y to $981 million, United States sales fell 4% Y/Y to $1.19 billion, Europe, Middle East, and Africa rose 2% Y/Y to $1.07 billion, and South, Central America, and the Caribbean increased 2% Y/Y to $314 million.
EBITDA declined 18% Y/Y to $601 million in the quarter, with a margin contracted 2.0ppt Y/Y to 16.5% in the quarter.
Lower volumes and weather-related maintenance activity impacted the EBITDA margin.
Segment-wise, operating EBITDA fell 27% Y/Y in Mexico, 20% Y/Y in the United States and 3% Y/Y in South and Central America and the Caribbean, while it increased 40% Y/Y in Europe, the Middle East and Africa segment.
Outlook: Cemex expects recurrent yearly EBITDA savings of at least $150 million in<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> 2025 and $350 million by 2027</a>.
Given the macroeconomic uncertainties and anticipated savings from Project Cutting Edge, the company continues to forecast flat EBITDA performance <a href="https://www.cemex.com/documents/d/cemex/1q25-presentation-english" target="_blank" rel="noreferrer noopener">for </a>2025.
Cemex remained optimistic about volume growth in EMEA and SCAC, anticipates improved performance in Mexico, and expects stable market conditions in the U.S. during the second half of 2025.
The company projects FCF to deliver $500 million in savings in 2025.
Price Action: CX shares are up 2.53% at $6.070&nbsp;premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45029247/unitedhealth-t-mobile-and-fiserv-are-among-top-12-large-cap-losers-last-week-apr-21-apr-25-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">UnitedHealth, T-Mobile And Fiserv Are Among Top 12 Large-Cap Losers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?</a></li>
</ul>

Equities

Mid Cap

Guidance

Cemex's Q1 Results Show Strong EMEA Growth, Offset by Mexican Market Struggles

Wedbush analyst Jay McCanless upgrades Tri Pointe Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPH#NYSE">TPH</a>) from Neutral to Outperform and raises the price target from $38 to $43.

Upgrades

Wedbush Upgrades Tri Pointe Homes to Outperform, Raises Price Target to $43

Mizuho analyst Ben Chaiken maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Outperform and lowers the price target from $62 to $59.

DKNG

Mizuho Maintains Outperform on DraftKings, Lowers Price Target to $59

Barclays analyst Luke Sergott maintains Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) with a Overweight and lowers the price target from $18 to $15.

AVTR

Barclays Maintains Overweight on Avantor, Lowers Price Target to $15

<ul>
<li>Success milestone reached in Scribe and Prevail's ongoing collaboration to accelerate in vivo therapeutics for neurological and neuromuscular diseases using Scribe's CRISPR technology</li>
<li>Companies to jointly present new preclinical data on self-inactivating AAV (siXAAV) technology from their collaboration at the 28th ASGCT Annual Meeting</li>
</ul>
Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced the achievement of a success milestone for one of the targets in its research collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), to develop in vivo CRISPR-based therapeutics for neurological and neuromuscular disorders. The success milestone marks Scribe's second such partnership achievement in 2025.
At the 28th American Society of Gene &amp; Cell Therapy (ASGCT) Annual Meeting, the companies will have a joint presentation titled "Self-Targeting CRISPR-CasX-Editor AAV Vectors Enable Potent and Controllable On-target Editing in the Murine CNS." The presentation will take place during the poster reception between 5:30 and 7:00 p.m. CT on Thursday, May 15, 2025, at the New Orleans Ernest N. Morial Convention Center.

Scribe Therapeutics And Prevail To Present New Preclinical Data On siXAAV Technology From Collaboration At ASGCT Annual Meeting

Mizuho analyst Gabriel Moreen downgrades Atmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATO#NYSE">ATO</a>) from Outperform to Neutral and lowers the price target from $165 to $164.

Downgrades

Mizuho Downgrades Atmos Energy to Neutral, Lowers Price Target to $164

Barclays analyst Benjamin Budish maintains Virtus Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>) with a Underweight and raises the price target from $149 to $150.

VRTS

Barclays Maintains Underweight on Virtus Inv, Raises Price Target to $150

CHKP

Check Point Software Achieves FedRAMP "In Process" Milestone

As of April 28, 2025, two stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Huntington Ingalls Industries Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>)</h3>
<ul>
<li>On April 11, Goldman Sachs analyst Noah Poponak upgraded the rating for Huntington Ingalls Indus from Sell to Buy and raised the price target from $145 to $234. The company's stock jumped around 10% over the past month and has a <a href="https://www.benzinga.com/quote/HII">52-week high of $285.81</a>.</li>
<li>RSI Value: 71.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>HII Price Action: Shares of Huntington Ingalls gained 1.9% to close at $226.05 on Friday.</li>
<li>Edge Stock Ratings: 30.06 Momentum score with Value at 60.22. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/hii"><img loading="lazy" decoding="async" width="491" height="192" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28072532/image-189.png" alt="" class="wp-image-890630" style="width:366px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28072532/image-189.png 491w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28072532/image-189-300x117.png 300w" sizes="(max-width: 491px) 100vw, 491px" /></a></figure>
<h3 class="wp-block-heading">Insteel Industries Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIIN#NYSE">IIIN</a>)</h3>
<ul>
<li>On April 17, the company posted better-than-expected quarterly sales. &#8220;We are encouraged by the strengthening demand for our products that began during our first quarter,&#8221; said H.O. Woltz III, President and CEO of Insteel. &#8220;The positive momentum we experienced through our second fiscal quarter was driven by improving business conditions and rising customer confidence, trends that are not fully reflected in the broader macroeconomic indices generally used to measure the strength of the construction industry. It is important to note that our results, and my comments, reflect conditions we experienced prior to the recent turmoil created by the changing tariff policy of the Trump Administration. &#8221; The company's stock gained around 25% over the past month and <a href="https://www.benzinga.com/quote/IIIN">has a 52-week high</a> of $35.52.</li>
<li>RSI Value: 71</li>
<li>IIIN Price Action: Shares of Insteel Industries fell 0.5% to close at $33.00 on Friday.</li>
</ul>
Unlock the rest of the BZ Edge Rankings and see <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how top stocks stack up</a>.
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Markets

Trading Ideas

IIIN

Top 2 Industrials Stocks That May Fall Off A Cliff This Quarter

Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRTS#NASDAQ">DRTS</a>, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT&#xAE;, announced today that it has successfully closed a registered direct offering (the "offering") whereby an affiliate of Oramed Pharmaceuticals Inc. ("Oramed") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORMP#NASDAQ">ORMP</a>) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share. The offering closed on April 28, 2025.&nbsp;&nbsp;
The total gross proceeds of the offering were approximately $36.9 million, before deducting estimated offering expenses payable by Alpha Tau. Alpha Tau intends to use the net proceeds from the offering for general corporate purposes, including research and development-related purposes in connection with its product candidates, for expansion of its manufacturing capabilities and for potential commercialization of its product candidates.

DRTS

ORMP

Oramed Pharma Closes Strategic Investment In Alpha Tau Medical; Oramed Affiliate Purchases About 14.1M Alpha Tau's Ordinary Shares $2.612/Shr

NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) will release earnings results for the first quarter, after the <a href="https://www.benzinga.com/quote/NXPI/earnings">closing bell on Monday, April 28.</a>
Analysts expect the Eindhoven, the Netherlands-based company to report quarterly earnings at $2.60 per share, down from $3.24 per share in the year-ago period. NXP Semiconductors projects to report quarterly revenue at $2.83 billion, compared to $3.13 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 11, NXP Semiconductors launched its new S32K5 series of automotive microcontrollers (MCU).
NXP Semiconductors shares slipped 0.01% to close at $193.55 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/NXPI/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barclays analyst Blayne Curtis maintained an Overweight rating and cut the price target from $230 to $190 on April 22, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Stifel analyst Tore Svanberg maintained a Hold rating and slashed the price target from $210 to $170 on April 17, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Citigroup analyst Christopher Danely maintained a Buy rating and slashed the price target from $290 to $220 on April 11, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Mizuho analyst Vijay Rakesh maintained an Outperform rating and increased the price target from $240 to $255 on Feb. 20, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Truist Securities analyst William Stein maintained a Buy rating and raised the price target from $245 to $258 on Feb. 18, 2025. This analyst has an accuracy rate of 82%.</li>
</ul>
Considering buying NXPI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="615" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033532/image-184-1024x615.png" alt="" class="wp-image-890283" style="width:547px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033532/image-184-1024x615.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033532/image-184-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033532/image-184-768x461.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033532/image-184.png 1108w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Earnings

NXPI

Top Wall Street Forecasters Revamp NXP Semiconductors Expectations Ahead Of Q1 Earnings

Barclays analyst David Anderson maintains Patterson-UTI Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTEN#NASDAQ">PTEN</a>) with a Overweight and lowers the price target from $11 to $8.

PTEN

Barclays Maintains Overweight on Patterson-UTI Energy, Lowers Price Target to $8

LTRY

Lottery.com Announces Company Update; Says Is Focused On Increasing Revenues Through Resuming Gaming Operations And Monetizing Sports.com And Completing Certain Acquisitions That Will Accelerate Profitability And Shareholder Value

Management

WestCX Appoints Sam Meckey As President; Effective Immediately

&nbsp;LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) (the "Company"), a provider of personal emergency response systems (PERS), health communication devices, and technology for the growing care economy, today announced changes to its Board committee assignments.
The LogicMark Board of Directors maintains an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee. The Board comprises four independent non-executive directors who serve on the Committees and the Company's Chief Executive Officer (CEO), totaling five directors.
The following new Board committee assignments reflect LogicMark's ongoing efforts to ensure that its Board effectively supports the Company's strategic direction and operational footprint.
Key updates include:
Carine Schneider, a director since October 2023, has been appointed Board Chair and remains a member of the Compensation Committee. She has helped grow B2B companies across multiple channels within capital markets, SaaS providers, and advisory services, utilizing AI and blockchain technology. She is the former President of Nasdaq Private Market and CEO of SaaS company Certent.
John Pettitt, who has served as a Director since March 2022, has been appointed Chair of the Nominating and Corporate Governance Committee. He continues to serve as a member of the Audit and Compensation Committees. John is a technology leader at Google with deep software and e-commerce expertise and a seasoned entrepreneur, having founded, edited, and IPO'd several companies.
Robert Curtis, a Director since July 2018, has been named Chair of the Compensation Committee, supported by Directors Schneider and Pettitt. He will continue to serve on the Audit Committee. He is a seasoned life sciences executive and strategic advisor with over 30 years of experience leading biotech and healthcare organizations, specializing in early-stage company development, scientific innovation, and strategic growth.
Barbara Gutierrez was appointed to the Board in May 2022 and remains Chair of the Audit Committee and is the Board's designated financial expert. She is a Certified Public Accountant and Chartered Management Accountant. Directors Pettitt and Curtis support her on the Audit Committee. Barbara is the CFO of Nasdaq-listed Modivcare and a highly accomplished board advisor with 30+ years of experience leading IPOs, complex financings, and growth strategies for public companies across the healthcare and technology sectors.
Chia-Lin Simmons, CEO of LogicMark and executive Board member since June 2021, continues to lead the Company's daily operations and does not serve on Board committees in line with governance best practices. Her extensive experience includes 30 years in the technology industry, including executive roles at Google, Audible / Amazon, and Harman International, and founding AI startup LookyLoo, reflecting her deep expertise in AI, IoT, and SaaS.
Carine Schneider, Board Chair, commented, "It's an honor to continue serving as part of the LogicMark Board as we help shape the Company's evolution into a leading-edge technology platform. This transformation, driven by our strategic focus on AI and machine learning, the launch of groundbreaking solutions like the Freedom Alert Max and the Aster App, and the value of our growing patent portfolio comprising 37 patents, 23 of which have been issued, and 17 currently filed since 2021, reflect our commitment to innovation and impact. As we redefine the customer experience and deepen our presence in the growing care economy, LogicMark is poised to thrive in the promising future of connected care." &nbsp;

LGMK

LogicMark Announces Changes To Board

Press Releases

Mynd.ai Closes $20 Million Sale of Non-strategic Business Unit and Announces Additional Strategic Actions to Enhance Operations, Strengthen Cash Position and Drive Long-Term Shareholder Value

Entertainment

General

Promethean wins Tech & Learning Awards of Excellence: Back to School 2024

Offerings

Mynd.ai Announces $10 Million Share Repurchase Program

The ActivPanel 10 is coming: Promethean's next-gen experience is built with choice and simplicity in mind

Mynd.ai's Promethean Brand to Release Transformational New Technology in First Quarter of 2025

The most anticipated, unified experience of 2025 is here: Introducing ActivPanel 10 and Promethean ActivSuite™

Mynd.ai's Promethean Brand to Release its Most Unified ActivPanel™ Experience yet with the Introduction of the ActivPanel 10 and Promethean ActivSuite™

Promethean wins Tech & Learning Awards of Excellence: Best of 2024

Mynd Announces Fiscal Year 2024 Results

Mynd.ai Announces CEO Transition

MYND

ATA Creativity Global - American Depositary Shares, each representing two common shares

ATA Creativity Global

Ambow Education Holding Ltd. American Depository Shares (each representing twenty (20) Class A Ordinary Shares)

Ambow Education Holding

Amesite

Bright Scholar Education Holdings Limited American Depositary Shares, each representing four Class A Ordinary Share

Bright Scholar Education

Chegg

51Talk Online Education Group American depositary shares, each representing 60 Class A ordinary shares

51 Talk Online Education

Skillful Craftsman Education Technology Limited - Ordinary Share

Skillful Craftsman

EpicQuest Education Group International Limited - Common Stock

EpicQuest Education Group

Four Seasons Education (Cayman) Inc. American Depositary Shares, each ADS representing 10 ordinary shares

Four Seasons Education

Genius Gr

Visionary Holdings

Jiade

Jianzhi Education Technology Group Company Limited - American Depositary Shares

Jianzhi Education Tech

Classover Holdings, Inc. - Class B Common Stock

Classover Holdings

Legacy Education

Jinxin Technology Holding Company - American Depositary Shares

Jinxin Technology Holding

Nerdy

NETCLASS TECHNOLOGY INC - Class A Ordinary Shares

Netclass Technology

QuantaSing Group Limited - American Depositary Shares

QuantaSing Group

Ruanyun Edai Technology Inc. - Ordinary shares

Ruanyun Edai Technology

Sunlands Technology Group American Depositary Shares, representing Class A ordinary shares

Comments

Mynd.ai

Notizie

Ultime notizie per Mynd.ai (AMEX:MYND) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO